Roche Holding AG (RHHVF)
OTCMKTS
· Delayed Price · Currency is USD
439.07
-9.96 (-2.22%)
At close: Mar 6, 2026
Roche Holding AG Employees
Roche Holding AG had 103,249 employees as of December 31, 2024. The number of employees decreased by 356 or -0.34% compared to the previous year.
Employees
103,249
Change (1Y)
-356
Growth (1Y)
-0.34%
Revenue / Employee
$773,849
Profits / Employee
$157,320
Market Cap
350.32B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 103,249 | -356 | -0.34% |
| Dec 31, 2023 | 103,605 | -8 | -0.01% |
| Dec 31, 2022 | 103,613 | 2,693 | 2.67% |
| Dec 31, 2021 | 100,920 | -545 | -0.54% |
| Dec 31, 2020 | 101,465 | 3,730 | 3.82% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Glass House Brands | 374 |
| Elite Pharmaceuticals | 68 |
| American Oncology Network | 1,914 |
| Northwest Biotherapeutics | 25 |
| CytoDyn | 13 |
| Silence Therapeutics | 116 |
| Vaxart | 105 |
| Tian'an Technology Group | 8 |
Roche Holding AG News
- 21 hours ago - Roche chairman still expects diagnostics hit from US tariffs - Reuters
- 1 day ago - New England Journal of Medicine publishes phase III ALLEGORY data showing Roche's Gazyva/Gazyvaro significantly reduces disease activity in the most common form of lupus - GlobeNewsWire
- 1 day ago - New England Journal of Medicine Publishes Phase III ALLEGORY Data Showing Genentech's Gazyva Significantly Reduces Disease Activity in the Most Common Form of Lupus - Business Wire
- 1 day ago - Roche, Zealand Pharma Obesity Drug Hits Goal in Midstage Trial - WSJ
- 2 days ago - Roche's obesity drug shows up to 10.7% weight loss in mid-stage trial - Reuters
- 2 days ago - Roche announces positive Phase II results for petrelintide, an amylin analog developed for people living with overweight and obesity - GlobeNewsWire
- 2 days ago - Genentech Announces Positive Phase II Results for Petrelintide, an Amylin Analog Developed for People Living With Overweight and Obesity - Business Wire
- 3 days ago - New survey demonstrates how diabetes limits day-to-day freedom for people around the world and highlights need for predictive tools - PRNewsWire